GeneDesign Company Profile

Ajinomoto Bio-Pharma Services, the contract development and manufacturing organization (CDMO) network of the Ajinomoto Group, refreshed its global brand and renewed its official website on October 5, 2026. This brand refresh features a new message and visual identity, clarifying its commitment to supporting client companies engaged in pharmaceutical development. Ajinomoto Bio-Pharma Services highlights its high level of expertise and scientific innovation specialized in various areas such as small molecules, peptides, gene therapy, and proteins, amidst the increasing complexity of biopharmaceutical development and manufacturing challenges. Furthermore, based on over 100 years of Ajinomoto Group's tradition and unique technologies, it offers reliable partnerships through quality, operational excellence, and sustainability. The new brand is set to be unveiled on the website and social media in the future.

Ajinomoto Bio-Pharma Services and Gene Design will enhance its contract development and production system from the early stages of development to late stages and commercialization by introducing large-scale production facilities. The establishment of the new base will expand the production volume per lot to the kilogram level. By combining our production capacity with the mass production technology of the Ajinomoto Group, a flexible and seamless supply system capable of producing over 100 kg, as opposed to the conventional μg manufacturing, will be established.